Talaj/iStock via Getty Images AbbVie’s (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech’s (BNTX)
Summary: AbbVie reported mixed Q2 2024 results, adding to my concerns of its growth potential.
JHVEPhoto The U.S. FDA’s approval Thursday of Bristol Myers Squibb’s (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline
mesh cube/iStock via Getty Images AbbVie (NYSE:ABBV) has submitted an NDA to the U.S. FDA
Michael Vi/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) announced Thursday its experimental therapy Tavapadon for
bravo1954/E+ via Getty Images A post-hoc analysis found that AbbVie’s (NYSE:ABBV) Rinvoq (upadacitinib) was found
Enes Evren/E+ via Getty Images AbbVie (NYSE:ABBV) subsidiary Allergan Cosmetics has launched Botox (onabotulinumtoxinA) in
AbbVie (NYSE:ABBV) declared $1.55/share quarterly dividend, in line with previous. Forward yield 3.19% Payable Nov. 15;
Summary: AbbVie’s stock has risen to an all-time high, raising the question of whether it’s
Summary: AbbVie delivered Y/Y growth in the second quarter despite Humira’s decline, with Skyrizi and